RxDoctor Payments Data

Akshai Janakiram Vitheswaran, MD

Hospitalist · Huntsville, ALNPI 1174727564

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 39.6% of the total.

$1,360in general payments, 2019–2025

Across 81 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$538
  • Pfizer$264
  • Novartis$107
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$93
  • E.r. Squibb & Sons, L.L.C.$80
  • AbbVie$67
  • plus $211 from 6 others

What the payments were for

  • Food & beverage$1,360100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,360 in reported general payments places this provider in the 85th percentile of 265 hospitalist providers in Alabama.

See all hospitalist providers in Alabama

Medicare billing

Part B allowed, 2024
$119,168
Medicare patients
355
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$62,693
TrulicityDulaglutide58$57,169
JanuviaSitagliptin Phosphate77$20,991
VraylarCariprazine Hcl22$15,776
JardianceEmpagliflozin40$12,216
NuedextaDextromethorphan Hbr/Quinidine15$11,701
Atorvastatin Calcium419$11,529
Breo ElliptaFluticasone/Vilanterol24$10,424
XareltoRivaroxaban30$9,558
Sucralfate181$9,246
EntrestoSacubitril/Valsartan26$9,121
FarxigaDapagliflozin Propanediol29$8,688
LantusInsulin Glargine,hum.Rec.Anlog76$8,613
MyrbetriqMirabegron37$8,585
LevemirInsulin Detemir36$7,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$264$62,693203 claims
MerckJanuvia$44$20,99177 claims
AbbVieVraylar$67$15,77622 claims
Johnson & JohnsonXarelto$538$9,55830 claims
NovartisEntresto$107$9,12126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 hospitalist providers in Alabama.

Other hospitalist in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →